Treatment Outcomes with Reduced-Dose Bortezomib in Adult Patients with Multiple Myeloma: A Single-Center Experience
نویسندگان
چکیده
Abstract Objectives Bortezomib vial-sharing is commonly employed to maximize the treatment of patients with multiple myeloma (MM) in resource-limited setting. This strategy minimizes delays but reduces dose bortezomib received by patient. Herein, we aimed determine patterns and outcomes Filipino MM who reduced-dose bortezomib. Methods The records 47 adult MM, seen at our institution from 2016 2019 treated bortezomib, were retrospectively reviewed. Results median age diagnosis was 55 years; 59.6% male. VCD (bortezomib, cyclophosphamide, dexamethasone) regimen most used (70.7%) bortezomib-based treatment. Among newly diagnosed patients, afforded an overall response rate 79.3%. survival not reached. Univariate analysis showed that hemoglobin level affected while age, calcium levels, choice induction regimen, depth all had impact on survival. Conclusion study first investigate real-world may provide initial evidence acceptable
منابع مشابه
modern surgical techniques in treatment of patients with cleft lip & cleft palate
چکیده ندارد.
15 صفحه اولBortezomib-based treatment for multiple myeloma patients with renal impairment
BACKGROUND Renal insufficiency is a common and severe complication of patients with multiple myeloma. The aim of this study was to evaluate bortezomib-based treatment for multiple myeloma patients with renal insufficiency. METHODS The Cochrane Library, Embase, PubMed, ISI, China National Knowledge Infrastructure, Chinese Biomedical Literature Service System, Chongqing VIP Database, and Wan Fa...
متن کاملTwo Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience
Multiple myeloma (MM) is the second most common hematological malignancy. The introduction of novel agents such as thalidomide, bortezomib, and lenalidomide in more recent years has significantly improved the response rate, progression‐free survival (PFS), and overall survival (OS) of MM patients.[1,2] However, alongside these benefits, a significant increased risk of developing secondary prima...
متن کاملPoor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience
Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases and has been reported to be associated with poor prognosis compared with other MM subtypes. The aim of the present study was to compare the effects of high-dose melphalan treatment and autologous stem cell transplantation (ASCT) on the survival of patients with IgD MM and patients with other MM subtypes. Between Novembe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Asian journal of oncology
سال: 2022
ISSN: ['2454-6798', '2455-4618']
DOI: https://doi.org/10.1055/s-0042-1751118